{"id":21145,"date":"2022-03-21T05:14:00","date_gmt":"2022-03-20T21:14:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=21145"},"modified":"2022-03-21T05:38:49","modified_gmt":"2022-03-20T21:38:49","slug":"bmj%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9amrna-1273%e7%96%ab%e8%8b%97%e5%af%b9%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92delta%ef%bc%8cmu%e5%92%8c%e5%85%b6%e4%bb%96%e5%8f%98%e5%bc%82%e6%a0%aa","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=21145","title":{"rendered":"[BMJ\u53d1\u8868\u8bba\u6587]\uff1amRNA-1273\u75ab\u82d7\u5bf9\u65b0\u51a0\u75c5\u6bd2delta\uff0cmu\u548c\u5176\u4ed6\u53d8\u5f02\u682a\u7684\u6548\u679c"},"content":{"rendered":"\n

Research<\/strong><\/p>\n\n\n\n

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study<\/h1>\n\n\n\n

Katia J Bruxvoort<\/a>, Lina S Sy, Lei Qian, et al<\/h3>\n\n\n\n

BMJ<\/em>\u00a02021;\u00a0375\u00a0doi:\u00a0https:\/\/doi.org\/10.1136\/bmj-2021-068848<\/a>\u00a0(Published 15 December 2021)Cite this as:\u00a0BMJ<\/em>\u00a02021;375:e068848<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Objectives<\/strong> To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination.<\/p>\n\n\n\n

Design<\/strong> Test negative case-control study.<\/p>\n\n\n\n

Setting<\/strong> Kaiser Permanente Southern California (KPSC), an integrated healthcare system.<\/p>\n\n\n\n

Participants<\/strong> Adult KPSC members with a SARS-CoV-2 positive test sent for whole genome sequencing or a negative test from 1 March 2021 to 27 July 2021.<\/p>\n\n\n\n

Interventions<\/strong> Two dose or one dose vaccination with mRNA-1273 (Moderna covid-19 vaccine) \u226514 days before specimen collection versus no covid-19 vaccination.<\/p>\n\n\n\n

Main outcome measures<\/strong> Outcomes included infection with SARS-CoV-2 and hospital admission with covid-19. In pre-specified analyses for each variant type, test positive cases were matched 1:5 to test negative controls on age, sex, race\/ethnicity, and specimen collection date. Conditional logistic regression was used to compare odds of vaccination among cases versus controls, with adjustment for confounders. Vaccine effectiveness was calculated as (1\u2013odds ratio)\u00d7100%.<\/p>\n\n\n\n

Results<\/strong> The study included 8153 cases and their matched controls. Two dose vaccine effectiveness was 86.7% (95% confidence interval 84.3% to 88.7%) against infection with the delta variant, 98.4% (96.9% to 99.1%) against alpha, 90.4% (73.9% to 96.5%) against mu, 96-98% against other identified variants, and 79.9% (76.9% to 82.5%) against unidentified variants (that is, specimens that failed sequencing). Vaccine effectiveness against hospital admission with the delta variant was 97.5% (92.7% to 99.2%). Vaccine effectiveness against infection with the delta variant declined from 94.1% (90.5% to 96.3%) 14-60 days after vaccination to 80.0% (70.2% to 86.6%) 151-180 days after vaccination. Waning was less pronounced for non-delta variants. Vaccine effectiveness against delta infection was lower among people aged \u226565 years (75.2%, 59.6% to 84.8%) than those aged 18-64 years (87.9%, 85.5% to 89.9%). One dose vaccine effectiveness was 77.0% (60.7% to 86.5%) against infection with delta.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions<\/strong> Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19. However, vaccine effectiveness against infection with the delta variant moderately declined with increasing time since vaccination.<\/p>\n","protected":false},"excerpt":{"rendered":"

Research Effectiveness of mRNA-1273 against delta, mu, […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21145"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21145"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21145\/revisions"}],"predecessor-version":[{"id":21499,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21145\/revisions\/21499"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}